Advertisement

Search Results

Advertisement



Your search for Rolf A. Stahel, MD matches 6 pages

Showing 1 - 6


lung cancer

Rolf A. Stahel, MD, on Results From the BELIEF Trial

Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung cancer without T790M mutation. The study was sponsored by The Spanish Lung Cancer Group and the European Thoracic Oncology...

lung cancer
gynecologic cancers
colorectal cancer
hepatobiliary cancer

Important Briefs from the 2011 European Multidisciplinary Cancer Congress

Nearly 16,000 people from 16 countries attended this year’s European Multidisciplinary Cancer Congress, held recently in Stockholm. The ASCO Post has featured several key reports from the meeting and will offer further coverage in upcoming issues. Additional noteworthy studies presented at the...

lung cancer

Local Treatments Fail to Improve Survival in Mesothelioma

The prognosis for malignant pleural mesothelioma remains dim, despite attempts to intensify treatment in the phase II SAKK 17/04 trial and other studies. The results of SAKK 17/04, presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, showed that the addition of...

issues in oncology

Practice-Changing Results at ESMO 2014

A record number of 19,859 attendees at the European Society for Medical Oncology (ESMO) 2014 Congress discussed changes to oncology that will soon have a positive impact on the care of patients around the world. “We are particularly pleased to see participants from 131 countries at the congress...

lung cancer

Combined EGFR and VEGF Inhibition Ameliorates the Impact of  the EGFR T790M Mutation in NSCLC

Treatment with erlotinib and bevacizumab (Avastin) may help overcome the poor prognosis associated with T790M mutations present at diagnosis in advanced non–small cell lung cancer (NSCLC), according to the results of the phase II BELIEF trial.1 At the 2015 European Cancer Congress, Rolf A. Stahel,...

lung cancer
issues in oncology

ALK-Positivity Prevalence on Immunohistochemistry and FISH in Resected Stage I to III Lung Adenocarcinoma

The European Thoracic Oncology Platform Lungscape ALK project is investigating the prevalence and prognostic impact of ALK-positivity in resected lung adenocarcinoma in a primarily European population. As reported in the Journal of Clinical Oncology by Blackhall and colleagues, the project has...

Advertisement

Advertisement



Advertisement